Breast Tomosynthesis Technique May Help Reduce Breast Cancer Screening Recall Rate

Share this content:
The U.S. FDA approved digital breast tomosynthesis for use with full-field digital mammography in breast imaging in 2011..
The U.S. FDA approved digital breast tomosynthesis for use with full-field digital mammography in breast imaging in 2011..

A new digital breast tomosynthesis technique has the potential to reduce the rate at which women are called back for additional examinations without sacrificing cancer detection, according to a study published in Radiology.1

In 2011, the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use with full-field digital mammography (FFDM) in breast imaging. When used with FFDM, DBT has been shown to improve cancer detection and reduce callbacks for additional examinations. However, the combination of the 2 methods requires a second radiation exposure to the breast and also slightly more time for women in breast compression.

Researchers have been exploring a relatively new approach in which the DBT images are used to create a synthesized 2-D (s2D) compilation image. The method has the potential to render FFDM unnecessary. Investigators compared the clinical performance of DBT-s2D with that of DBT-FFDM and FFDM alone. They studied 78,810 screening mammograms performed from 2011 to 2016. In the study group, 32,076 women were screened with FFDM, 30,561 women were screened using DBT-FFDM, and 16,173 women were screened using DBT-s2D.

The study demonstrated that DBT-s2D's recall rate was only 4.3% compared with 5.8% for DBT-FFDM. Overall cancer detection rates were similar. However, DBT-s2D detected 76.5% of invasive cancers compared with 61.3% for DBT-FFDM. At 3.6%, the false ̶positive rate for DBT-s2D was significantly lower than the 5.2% rate for DBT-FFDM. The positive predictive value of biopsy for DBT-s2D was 40.8% compared to 28.5% for DBT-FFDM.

Reference

1. Aujero MP, Gavenonis SC, Benjamin R, et al. Clinical Performance of Synthesized Two-dimensional Mammography Combined with Tomosynthesis in a Large Screening Population. Radiology. 2017 Feb 21:162674. doi: 10.1148/radiol.2017162674 [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs